Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SB-525 Gene Therapy Promising for Hemophilia A

Key clinical point: Interim data suggest that SB-525, an investigational gene therapy, may be safe and effective for patients with severe hemophilia A.

Major finding: Two of eight patients treated with SB-525 have achieved normal factor VIII levels.

Study details: A phase 1/2 trial with data on eight patients with severe hemophilia A.

Disclosures: The trial is sponsored by Sangamo Therapeutics in collaboration with Pfizer.